What is the proposed settlement between CVS Health and the FTC about?

The proposed settlement between CVS Health and the Federal Trade Commission concerns insulin pricing practices by CVS's pharmacy benefit management unit, Caremark.

When is the CVS Health insulin pricing settlement expected to conclude?

CVS Health expects the settlement process to conclude in the coming weeks, with final terms pending official confirmation.

Has CVS Health's Caremark unit been scrutinized for pricing?

Yes, pharmacy benefit managers, including CVS's Caremark unit, have faced a decade of scrutiny from regulators and lawmakers over pricing practices.

Home / Business and Economy / CVS Reaches Insulin Pricing Deal With FTC

CVS Reaches Insulin Pricing Deal With FTC

24 Mar

•

Summary

CVS Health has agreed to a proposed settlement with the FTC.
The agreement concerns insulin pricing practices by its Caremark unit.
The settlement is expected to be finalized in the coming weeks.

CVS Reaches Insulin Pricing Deal With FTC

CVS Health has reached a proposed settlement agreement with the Federal Trade Commission (FTC) concerning insulin pricing. This agreement addresses a decade of regulatory and legislative scrutiny faced by pharmacy benefit managers regarding their pricing strategies.

The company’s pharmacy benefit management division, Caremark, has reportedly maintained a focus on lowering prescription drug expenses. This proposed settlement is a significant step in resolving ongoing investigations into these practices.

CVS Health anticipates that the settlement process will be finalized in the upcoming weeks. The final terms of the agreement are still pending and will be officially confirmed once the settlement is formally concluded.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.